“We are excited to expand our presence in the greater Columbus area, and specifically New Albany. We believe the innovation platform we are bringing to the region is synergistic with and reflective of the collaborative environment that I first noticed when I came to Ohio.”
Kelly Ganjei, AmplifyBio CEO and President
AmplifyBio, a biotechnology contract research organization seeking to advance quality and innovation in health and advanced therapies, plans to join Amgen and other industry leaders in the New Albany International Business Park’s growing Health & Life Sciences Cluster. The Battelle spin-off announced an investment of approximately $150 million in a new 350,000-square-foot facility here. Across the globe, rapid advances in drug discovery and delivery together with ever-evolving technologies are driving unprecedented growth in the sector.
“When our clients need to quickly establish and scale operations, they know that they can achieve success in New Albany because we have made all the necessary investments to welcome them while reducing their development costs,” said Jennifer Chrysler, New Albany director of community development. New Albany offers technology- and shovel ready sites, redundant, reliable utilities and the ability to fast track project planning and permitting to expedite construction and return on investment.
Central Ohio’s expanding life sciences ecosystem is bolstered by strong talent in biosciences, technology and engineering, postsecondary educational institutions, clinical research hospitals and private research institutions like Battelle.
AmplifyBio is expanding to meet significant unmet market demand with a large focus on advanced therapies such as cell and gene therapy products. Its new facility at 9885 Innovation Campus Way will create 132 new jobs. The company’s existing West Jefferson location on a 30-acre campus at 1425 Plain-City Georgesville Road, which currently has 155 employees, will see the creation of 99 new jobs. In addition, 32 new corporate jobs will be added at a location that is yet to be determined.